Optimal antiplatelet therapy in patients with acute coronary syndrome, undergoing to primary percutaneous coronary angioplasty
The article presents the results of primary percutaneous coronary angioplasty (PCA) in treatment of patients with acute coronary syndrome (ACS), the efficacy, safety and the needfor ticagrelor in order to preoperative preparation. During the period from March to July 2012 PCA urgently completed 78 patients with ACS, with pre-preparation antiplatelet therapy with ticagrelor. Pre-loading dose was 180 mg. Results of treatment of patients showed high efficiency PCA in ACS. Preoperative use of ticagrelor reduced the risk of intraoperative and postoperative complications, the frequency of intraoperative use of inhibitors IIb /IIIa receptor inhibitors, and reduce treatment costs.